Clinical Trial Update: Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating whether adding gefitinib to chemotherapy improves outcomes in advanced lung adenocarcinoma with sensitive EGFR mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Adenocarcinoma | Phase 2 | Status: UNKNOWN